Universal International Scientific Journal
114
Eminov Ravshanjon Ikromjon ugli
assistant, Department of Faculty and Hospital Surgery, Fergana Medical Institute of Public Health,
Fergana,
Uzbekistan
https://orcid.org/0000-0002-4290-9840
Abstract:
The integration of artificial intelligence (AI) and cancer genomics has transformed
precision oncology, enabling early detection and personalized treatment strategies. AI techniques, including
machine learning and deep learning, analyze complex genomic data to uncover mutations and identify
biomarkers. These approaches enhance early cancer detection through tools like liquid biopsies and
optimize personalized treatments by predicting drug responses and refining immunotherapy. Despite
significant advancements, challenges such as data privacy, model interpretability, and clinical integration
remain. Future efforts focus on interdisciplinary collaboration, explainable AI, and federated learning to
overcome these hurdles and further revolutionize cancer care.
Keywords:
cancer genomics, artificial intelligence, early detection, personalized treatment, precision
oncology.
Universal Xalqaro Ilmiy Jurnal
Jurnalning bosh sahifasi:
CANCER GENOMICS AND AI: CREATING AI MODELS TO IDENTIFY GENOMIC
ALTERATIONS IN CANCER, ENHANCING EARLY DETECTION AND PERSONALIZED
TREATMENT STRATEGIES
Universal International Scientific
Year: 2025 Issue: 2 Volume: 1
Published: 23.01.2025
International indexes
Universal International Scientific Journal
11
5
Annotatsiya:
Sun'iy intellekt (AI) va saraton genomikasining integratsiyasi aniq onkologiyani
o'zgartirib, erta aniqlash va shaxsiylashtirilgan davolash strategiyalarini yaratishga imkon berdi. AI
texnikasi, jumladan, mashinani o'rganish va chuqur o'rganish, mutatsiyalarni aniqlash va biomarkerlarni
aniqlash uchun murakkab genomik ma'lumotlarni tahlil qiladi. Ushbu yondashuvlar suyuq biopsiya kabi
vositalar orqali saratonni erta aniqlashni yaxshilaydi va dori reaktsiyalarini bashorat qilish va
immunoterapiyani takomillashtirish orqali shaxsiylashtirilgan davolanishni optimallashtiradi. Muhim
yutuqlarga qaramay, ma'lumotlarning maxfiyligi, modelni talqin qilish va klinik integratsiya kabi
muammolar saqlanib qolmoqda. Kelajakdagi sa'y-harakatlar fanlararo hamkorlik, tushuntiriladigan AI va
ushbu to'siqlarni engib o'tish va saraton kasalligini davolashni yanada inqilob qilish uchun federal
o'rganishga qaratilgan.
Kalit so‘zlar:
saraton genomikasi, sun'iy intellekt, erta aniqlash, shaxsiylashtirilgan davolash, aniq
onkologiya.
Аннотация:
Интеграция искусственного интеллекта (ИИ) и геномики рака преобразила
точную онкологию, обеспечив раннее выявление и персонализированные стратегии лечения.
Методы ИИ, включая машинное обучение и глубокое обучение, анализируют сложные геномные
данные для обнаружения мутаций и идентификации биомаркеров. Эти подходы улучшают раннее
выявление рака с помощью таких инструментов, как жидкая биопсия, и оптимизируют
персонализированное лечение, прогнозируя реакцию на лекарства и совершенствуя
иммунотерапию. Несмотря на значительные достижения, остаются такие проблемы, как
конфиденциальность данных, интерпретируемость моделей и клиническая интеграция. Будущие
усилия сосредоточены на междисциплинарном сотрудничестве, объяснимом ИИ и федеративном
обучении для преодоления этих препятствий и дальнейшей революции в лечении рака.
Ключевые слова:
геномика рака, искусственный интеллект, раннее выявление,
персонализированное лечение, точная онкология.
Language:
English
Citation:
Eminov , R. (2025). CANCER GENOMICS AND AI: CREATING AI MODELS TO
IDENTIFY GENOMIC ALTERATIONS IN CANCER, ENHANCING EARLY DETECTION AND
PERSONALIZED TREATMENT STRATEGIES. Universal International Scientific Journal, 2(1), 114–
https://doi.org/10.69891/3060-4540.2025.56.98.001
Doi:
https://doi.org/10.5281/zenodo.14759506
Google scholar:
Crosreff doi:
https://doi.org/10.69891/3060-4540.2025.39.71.001
INTRODUCTION
Understanding cancer driven by
Universal International Scientific Journal
11
6
genetic and epigenetic alterations has been
significantly advanced through genomic
studies, which have been further enhanced
by the integration of artificial intelligence
(AI)
and
machine
learning
(ML)
technologies. Genomic technologies, such
as next-generation sequencing (NGS) and
gene
expression
profiling,
have
revolutionized
cancer
research
by
providing detailed insights into the genetic
basis of cancer, enabling early diagnosis
and personalized treatment strategies.
These
technologies
allow
for
the
identification of specific genetic markers
associated with various cancer types,
facilitating precision medicine that tailors
interventions based on individual genetic
profiles[2, 11]. AI and ML have further
transformed genomic data analysis by
enabling the processing of vast amounts of
data to uncover hidden patterns and predict
disease risk with high precision. AI-driven
mutation detection, for instance, can
accurately identify genetic mutations
linked to cancer, enhancing predictive
capabilities and supporting personalized
medicine[25,
29].
Moreover,
AI's
integration with bioinformatics tools and
clinical databases aids in the discovery and
validation
of
new
biomarkers
and
therapeutic targets, which are crucial for
precision oncology[2, 29]. AI systems,
such as SmartMTB, provide advanced
interpretation of NGS reports, offering
personalized treatment strategies and
improving patient outcomes by matching
clinical cases with real-time updates on
treatment options[13]. Additionally, AI
frameworks like DrOGA and other ML
models have been developed to classify
driver mutations, providing visual and
clinical explanations that support targeted
therapies based on personal genomic
data[47]. The use of AI in genomic studies
not only enhances early cancer detection
but also enables the development of
personalized treatment plans, improving
diagnostic accuracy and treatment efficacy.
However, challenges such as data privacy,
model interpretability, and integration into
clinical practice remain, necessitating
ongoing research and development to fully
realize
AI's
potential
in
precision
oncology[29, 32, 48]. Overall, the
convergence of genomic technologies and
AI
holds
immense
promise
for
revolutionizing cancer care, offering more
precise prevention, early detection, and
personalized treatment strategies that could
significantly improve patient outcomes[11,
20, 32].
GENOMIC ALTERATIONS IN
CANCER
Genetic and epigenetic alterations are
fundamental to cancer development,
involving changes that affect gene
expression and cellular pathways critical
for proliferation, differentiation, and
apoptosis. Genetic alterations include
mutations in oncogenes and tumor
suppressor genes, while epigenetic changes
involve modifications in DNA methylation
and histone acetylation, often regulated by
chromatin-modifying enzymes[9]. Next-
Universal International Scientific Journal
11
7
generation sequencing (NGS) technologies
have revolutionized the analysis of these
alterations by enabling comprehensive
genomic profiling. NGS allows for the
parallel sequencing of thousands to
millions of DNA or RNA fragments,
significantly increasing the speed and
reducing the cost of sequencing compared
to traditional methods like Sanger
sequencing[19].
This
technological
advancement facilitates the identification
of somatic mutations, copy number
variations, and other genomic alterations
across entire genomes or exomes, which is
crucial for understanding cancer biology
and
developing
precision
medicine
strategies[1, 34]. In breast cancer, for
instance, NGS has been instrumental in
identifying clinically significant genomic
alterations that guide therapy decisions,
enhancing
the
precision
of
cancer
treatment[37]. However, the vast amount
of data generated by NGS presents
challenges
in
data
management,
interpretation, and integration into clinical
practice. The complexity and volume of
genomic
data
necessitate
advanced
computational tools and algorithms for
effective analysis and interpretation[1, 43].
Moreover, the integration of genomic data
into clinical settings requires skilled
genetic counselors to bridge the gap
between genomic insights and patient
care[23]. As the field progresses, there is a
growing need for machine learning and
artificial intelligence to manage and
interpret the complex "-omics" data, which
could further refine precision medicine
approaches[37]. Despite these challenges,
the potential of NGS to transform cancer
diagnosis
and
treatment
remains
significant, underscoring the importance of
continued
technological
and
methodological advancements in genomic
research[43].
AI IN CANCER GENOMICS
AI techniques, including machine
learning, deep learning, natural language
processing,
and
multi-omics
data
integration,
are
increasingly
being
leveraged to identify genomic alterations in
cancer. These technologies enable the
analysis of vast and complex datasets,
leading to more precise cancer diagnosis,
classification,
and
treatment.
By
integrating
various
data types
and
employing advanced algorithms, AI can
uncover hidden patterns and predict
disease risk with high accuracy. The
following sections detail how these AI
techniques are applied in cancer genomics,
supported by key case studies.
MACHINE LEARNING AND
DEEP LEARNING IN GENOMIC
ALTERATION DETECTION
• Machine learning (ML) and deep
learning
(DL)
models,
such
as
convolutional neural networks (CNNs) and
recurrent neural networks (RNNs), are
used to process genomic data and identify
genetic
mutations,
including
single
nucleotide polymorphisms (SNPs) and
structural variations. These models can
predict
disease
risk
and
support
Universal International Scientific Journal
11
8
personalized medicine by analyzing next-
generation sequencing data and clinical
databases[25].
• AI-driven systems have shown
improved
diagnostic
outcomes
over
conventional methods in fields like
mammography for breast cancer and CT
for lung cancer. These systems can detect
cancer-related genes and biomarkers,
aiding in precision medicine by tailoring
treatments
to
the
patient's
genetic
profile[32].
Multi-omics data integration
• Multi-omics
data
integration
involves
combining
genomics,
epigenomics, transcriptomics, proteomics,
and
metabolomics
to
provide
a
comprehensive view of cancer's molecular
landscape. This approach helps identify
subtle
molecular
fingerprints
and
biomarkers that might be overlooked when
analyzing individual data types[49].
• Graph neural networks, such as
GGraphSAGE, have been developed to
predict cancer driver genes by integrating
multi-omics data with protein-protein
interaction
networks.
This
method
outperforms
traditional
computational
methods and identifies tumor-specific
driver
genes,
enhancing
precision
medicine[12].
AI-DRIVEN MUTATION
DETECTION AND PREDICTION
• AI-based variant effect predictors
(VEPs),
like
AlphaMissense,
utilize
protein structure modeling to predict the
pathogenic effects of mutations. These
tools have demonstrated high accuracy in
identifying known cancer driver mutations,
particularly in tumor suppressor genes[5].
• The DrOGA framework employs
machine learning and deep learning
techniques to classify driver somatic non-
synonymous mutations, providing a high-
precision tool for analyzing genomic
alterations in cancer. This framework
supports precision oncology by enabling
targeted therapies based on personal
genomic data[47].
CHALLENGES AND FUTURE
DIRECTIONS
• Despite the promise of AI in cancer
genomics, challenges remain, including
data heterogeneity, privacy concerns, and
the need for standardized data collection
and analysis methods. Addressing these
issues is crucial for the successful
integration of AI into clinical practice[18].
• Future trends in cancer diagnostics
will likely involve deeper integration of AI
and big data technologies, enabling more
precise prevention and treatment strategies.
This approach could extend to early cancer
identification and prevention through
proper intervention[32].
While AI techniques offer significant
advancements in identifying genomic
alterations in cancer, there are still hurdles
to overcome, such as algorithmic biases
and the integration of AI systems into
clinical workflows. Ethical considerations,
data protection, and the interpretability of
AI models are critical areas that require
attention to ensure the responsible and
Universal International Scientific Journal
11
9
effective use of AI in cancer genomics[25,
32].
ENHANCING EARLY CANCER
DETECTION WITH AI
Artificial
intelligence
(AI)
has
emerged as a transformative tool in the
identification of genetic and molecular
biomarkers, analysis of circulating tumor
DNA (ctDNA), and the development of
non-invasive population screening tools for
early-stage cancer detection. AI models,
such as deep generative models and neural
networks, have shown significant promise
in analyzing complex biological data to
identify biomarkers indicative of early-
stage cancers. For instance, the use of
variational auto-encoders in analyzing
orphan
non-coding
RNAs
has
demonstrated
high
sensitivity
and
specificity in detecting early-stage lung
cancer, outperforming traditional methods
by a substantial margin[22]. Similarly, AI
combined with liquid biopsies has been
proposed for ovarian cancer screening,
leveraging
the
detection
of
tumor
components and genetic changes in blood
samples to facilitate early diagnosis[30].
The integration of AI with advanced
techniques like surface-enhanced Raman
scattering (SERS) has also been effective
in distinguishing cancer patients from
healthy individuals with high accuracy,
further supporting its potential in early
cancer detection[35].
Circulating tumor DNA (ctDNA) is
another promising biomarker for early
cancer detection, as it reflects tumor-
specific genetic alterations. AI-driven
approaches have been employed to
enhance the sensitivity and specificity of
ctDNA assays, although challenges remain
in detecting very small tumors and
localizing the disease[28, 39]. Despite
these challenges, ctDNA holds potential as
a prognostic tool and for monitoring
disease
progression
and
treatment
outcomes[28]. Moreover, AI systems
utilizing noncoding RNA biomarkers have
achieved high accuracy in classifying
multiple cancer types, suggesting their
utility in large-scale cancer screening[4].
The
development
of
non-invasive
molecular biomarkers, such as those found
in liquid biopsies, is further supported by
AI's ability to process and analyze vast
amounts of genomic and epigenetic data,
thereby enhancing early cancer diagnosis
and prognosis[41, 45].
Overall, AI's role in cancer detection
is multifaceted, involving the identification
of novel biomarkers, the enhancement of
existing diagnostic techniques, and the
potential to revolutionize population
screening through non-invasive methods.
While significant progress has been made,
ongoing research is essential to address
current limitations and fully realize AI's
potential in clinical practice[6, 16].
AI FOR PERSONALIZED CANCER
TREATMENT
Artificial
intelligence
(AI)
is
significantly
advancing
personalized
cancer treatment by enhancing the
prediction of drug responses, optimizing
Universal International Scientific Journal
1
20
immunotherapy, and dynamically adapting
treatment plans. AI-driven models analyze
vast datasets, including genomic, clinical,
and imaging data, to identify patterns that
traditional
methods
might
overlook,
thereby enabling the development of
tailored therapies specific to each patient’s
genetic makeup and disease profile[38]. By
integrating multi-omics data, electronic
health records, and empirical evidence, AI
frameworks can predict optimal treatment
courses, improving patient outcomes
through personalized medicine[7]. In drug
response prediction, AI leverages machine
learning algorithms to analyze genetic
variations that influence drug metabolism,
efficacy, and toxicity, allowing healthcare
providers to predict which medications and
dosages will be most effective for
individual patients, thus reducing adverse
drug reactions[8]. AI also plays a crucial
role
in
optimizing
immunotherapy,
particularly through the use of immune
checkpoint inhibitors (ICIs). By modeling
the tumor immune microenvironment
(TIME) and employing deep reinforcement
learning, AI can personalize ICI therapy
schedules, enhancing treatment efficacy
based
on
the
tumor's
immune
characteristics[42].
Furthermore,
AI's
ability to continuously learn and integrate
new data allows for the dynamic adaptation
of
treatment
plans,
ensuring
that
therapeutic strategies remain aligned with
the evolving nature of the disease and the
patient's response[10]. Despite these
advancements, challenges such as data
privacy, model transparency, and potential
biases in AI systems remain, necessitating
ongoing efforts to refine AI applications in
oncology[27, 40]. Overall, AI's integration
into personalized cancer treatment holds
transformative potential, promising more
effective,
individualized
care
and
improved patient outcomes[3, 10].
CHALLENGES AND LIMITATIONS
The
integration
of
artificial
intelligence (AI) in personalized cancer
treatment presents several key challenges
and limitations, primarily revolving around
biases in datasets, model interpretability,
and clinical translation. One of the
foremost challenges is the presence of
biases in clinical observational data, which
can significantly impact the performance
of AI models used for counterfactual
outcome
prediction
and
biomarker
identification.
These
biases,
often
stemming from unbalanced datasets and
limited feature scopes, can lead to skewed
treatment recommendations that do not
accurately reflect the diverse patient
populations they are meant to serve[24,
33]. Moreover, algorithmic biases can
exacerbate existing health disparities,
particularly affecting marginalized patient
groups, thus necessitating a thoughtful and
inclusive approach to AI model design and
implementation[14, 14]. Another critical
limitation is the interpretability of AI
models. The complexity of AI algorithms,
especially those involving deep learning,
often results in "black box" models that are
difficult for clinicians to interpret and trust,
Universal International Scientific Journal
1
2
1
which poses a barrier to their adoption in
clinical
settings[40].
This
lack
of
transparency can hinder the clinical
translation of AI-driven insights, as
healthcare providers may be reluctant to
rely on recommendations that they cannot
fully understand or explain to patients[17].
Additionally, the high-dimensional nature
of biological data and the need for
empirical validation of AI predictions
further complicate the clinical application
of these technologies[3, 36]. Despite these
challenges, AI holds significant promise
for
enhancing
personalized
cancer
treatment by enabling more precise and
individualized
therapeutic
strategies,
provided that these limitations are
addressed
through
interdisciplinary
collaboration and the development of
robust, transparent, and equitable AI
systems[38, 44].
FUTURE DIRECTIONS
The future directions for AI in cancer
treatment are poised to revolutionize the
field through emerging technologies,
clinical implementation strategies, and
interdisciplinary
collaborations.
AI
technologies,
particularly
machine
learning and deep learning, are enhancing
precision medicine by enabling more
personalized cancer treatments. These
technologies
analyze
vast
datasets,
including genomic, clinical, and imaging
data, to identify patterns that inform
tailored therapies specific to each patient's
genetic makeup and disease profile[3, 38].
AI is also transforming drug discovery and
development
by
accelerating
the
identification of potential drug candidates,
thus reducing the time and costs associated
with developing new treatments[26]. In
clinical settings, AI-driven tools are
improving
diagnostic
accuracy
and
treatment planning, with applications such
as computer vision-assisted image analysis
and advanced clinical decision support
systems that integrate genomics and
clinomics[46]. The integration of AI in
cancer research is further supported by the
development of AI-equipped software as
medical devices, which are being approved
by
regulatory
bodies[31].
However,
challenges
such
as
data
security,
infrastructure needs, and the "black box"
nature of AI models, which can limit
transparency and reproducibility, must be
addressed to fully realize AI's potential in
oncology[26,
46].
Interdisciplinary
collaborations are crucial in overcoming
these challenges, as they bring together
expertise
from
fields
such
as
bioinformatics, oncology, and computer
science to refine AI models and ensure
their clinical applicability[21]. The future
of AI in cancer treatment also involves
leveraging multimodal data elements to
create more complex models that better
approximate organic systems, potentially
leading to highly personalized treatment
plans that consider all aspects of a patient's
health[46]. As AI continues to evolve, its
role in oncology is expected to expand,
driving advancements in both clinical
practice and research, ultimately making
Universal International Scientific Journal
1
22
cancer treatment more precise, effective,
and accessible worldwide[15, 38].
CONCLUSION
The
integration
of
artificial
intelligence (AI) with cancer genomics
represents a transformative advancement in
precision oncology, offering new pathways
for early detection and personalized
treatment. By leveraging AI techniques
such as machine learning and deep
learning, researchers can analyze complex
datasets to uncover critical genomic
alterations, identify novel biomarkers, and
optimize treatment strategies tailored to
individual patients. Despite challenges
related
to
data
privacy,
model
interpretability,
and
clinical
implementation,
the
continued
development of AI technologies holds
immense potential to revolutionize cancer
care. As interdisciplinary collaborations
advance and emerging technologies are
integrated, AI-driven approaches will pave
the way for more effective, equitable, and
accessible
cancer
diagnostics
and
treatments worldwide.
REFERENCES:
1. Perry Evans, Yong Kong, Michael Krauthammer Computational analysis in cancer exome
sequencing. 2014.C. 219–227.
2. Alexis J. Clark, James W. Lillard A Comprehensive Review of Bioinformatics Tools for
Genomic Biomarker Discovery Driving Precision Oncology // Genes. 2024.
3. Anwar Shams Leveraging State-of-the-Art AI Algorithms in Personalized Oncology: From
Transcriptomics to Treatment // Diagnostics. 2024. № 19 (14). C. 2174–2174.
4. Anyou Wang [и др.]. Noncoding RNAs and deep learning neural network discriminate multi-
cancer types. // arXiv: Molecular Networks. 2021.
5. Christopher J. Fong [и др.]. Abstract 1252: AI-derived predictions improve identification of real-
world cancer driver mutations // Cancer Research. 2024.
6. Clare Fiala [и др.]. Can a Broad Molecular Screen Based on Circulating Tumor DNA Aid in
Early Cancer Detection 2020. № 6 (5). C. 1372–1377.
7. Dr.Vinod Vegesna AI-Driven Personalized Medicine: A Frame Work for Tailored Cancer
Treatment // International journal of innovative research in advanced engineering. 2024. № 06 (11). C.
747–752.
8. Ejike Innocent Nwankwo [и др.]. AI in personalized medicine: Enhancing drug efficacy and
reducing adverse effects // International medical science research journal. 2024. № 8 (4). C. 806–833.
9. Eric R. Fearon Genetic and Epigenetic Alterations in Cancer 2020.C. 188–203.
10. Hakan Eraslan AI-Mediated Methods For Cancer Treatment 2024. № 1 (8). C. 25–25.
11. Hatijar Hatijar [и др.]. Application of Genomic Technology in Early Diagnosis and
Personalized Treatment for Cancer Patients // Global international journal of innovative research. 2024.
№ 1 (2). C. 384–391.
12. Hongzhi Song [и др.]. Identification of Cancer Driver Genes by Integrating Multiomics Data
with Graph Neural Networks // Metabolites. 2023. № 3 (13). C. 339–339.
13. Hui Chen [и др.]. Abstract 2315: AI-enabled precision oncology era: Advanced and interactive
interpretation of next-gneneration sequencing (NGS) reports // Cancer Research. 2024.
14. Irene Dankwa-Mullan, Dilhan Weeraratne Artificial Intelligence and Machine Learning
Technologies in Cancer Care: Addressing Disparities, Bias, and Data Diversity // Cancer Discovery.
2022. (12). C. 1423–1427.
15. Jin Xu, Jianhui Yang, Xianjun Yu Novel research and future prospects of artificial intelligence
in cancer diagnosis and treatment // Journal of Hematology & Oncology. 2023. (16).
Universal International Scientific Journal
1
23
16. K. Aditya Shastry, H. A. Sanjay Cancer diagnosis using artificial intelligence: a review //
Artificial Intelligence Review. 2021. C. 1–33.
17. Kungu Erisa The Significance of Artificial Intelligence and Machine Learning in the
Identification of Immunotherapy Targets for Cancer: Advances, Challenges, and Future Directions 2024.
18. Lise Wei [и др.]. Artificial intelligence (AI) and machine learning (ML) in precision oncology:
a review on enhancing discoverability through multiomics integration. // British Journal of Radiology.
2023. C. 20230211–20230211.
19. Lorenzo Monserrat Genetic and Genomic Technologies: Next Generation Sequencing for
Inherited Cardiovascular Conditions 2018.C. 97–117.
20. Manuel Schürch [и др.]. Towards AI-Based Precision Oncology: A Machine Learning
Framework for Personalized Counterfactual Treatment Suggestions based on Multi-Omics Data //
arXiv.org. 2024. (abs/2402.12190).
21. Md. Noumil Tousif [и др.]. Revolutionizing Cancer Therapy: The Role of Artificial Intelligence
in Enhancing Treatment Efficacy 2023.C. 89–93.
22. Mehran Karimzadeh [и др.]. Deep generative AI models analyzing circulating orphan non-
coding RNAs enable detection of early-stage lung cancer // Nature Communications. 2024. № 1 (15).
23. Michael J. Hall [и др.]. Incorporating genomic testing using next-generation sequencing (NGS)
into clinical practice: Genetic counselors’ (GC) experience, knowledge, and perceived competence. //
Journal of Clinical Oncology. 2014. (32).
24. Michael Vollenweider [и др.]. Learning Personalized Treatment Decisions in Precision
Medicine: Disentangling Treatment Assignment Bias in Counterfactual Outcome Prediction and
Biomarker Identification // arXiv.org. 2024. (abs/2410.00509).
25. Murali Krishna Pasupuleti AI-Driven Mutation Detection: Transforming Genomic Data into
Insights for Disease Prediction 2024. C. 1–28.
26. Nizamullah FNU [и др.]. AI in Healthcare: Breaking New Ground in the Management and
Treatment of Cancer // Asian journal of engineering, social and health. 2024. № 10 (3). C. 2325–2343.
27. NULL AUTHOR_ID, Gaurav G Khandalkar, NULL AUTHOR_ID Artificial Intelligence
Could be the Personalized Treatment Strategy for Cancer // International journal of pharmaceutical
quality assurance. 2024. № 02 (15). C. 1017–1022.
28. Parikshit Bittla [и др.]. Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early
Detection of Cancer: A Systematic Review // Cureus. 2023. (15).
28. Mirakbarova, M., Xojamshukurov, N., Otajonov, A., Abdullayev, X., & Abdutolibov, M.
(2024). TENEBRIO MOLITOR LICHINKASIDAN OLINGAN YOG’NING MIKROBIOLOGIK
TAHLILI. Universal xalqaro ilmiy jurnal, 1(2), 60-66.
29. Pedro Henrique Zeraik Viduedo [и др.]. Harnessing the power of ai and machine learning for
next-generation sequencing data analysis: a comprehensive review of applications, challenges, and future
directions in precision oncology // Revista Ibero-Americana de Humanidades, Ciências e Educação. 2024.
№ 8 (10). C. 2898–2904.
30. Peter Hofland Early Detection of Ovarian Cancer May be Possible with Combination of
Artificial Intelligence and Liquid Biopsies // Onco’zine. 2024.
31. Ryuji Hamamoto [и др.]. Current status and future direction of cancer research using artificial
intelligence for clinical application // Cancer Science. 2024.
32. Sabira Arefin IDMap: Leveraging AI and Data Technologies for Early Cancer Detection //
International Journal of scientific research and management. 2024.
33. Sarthak Bhatia [и др.]. Uncovering the Challenges From Algorithmic Bias Affecting the
Marginalized Patient Groups in Healthcare // Social Science Research Network. 2024.
34. Serena Nik-Zainal Insights into cancer biology through next-generation sequencing. // Clinical
Medicine. 2014. (14).
35. Shilian Dong [и др.]. Early cancer detection by serum biomolecular fingerprinting spectroscopy
with machine learning // eLight. 2023. (3).
Universal International Scientific Journal
1
2
4
36. Shriniket Dixit [и др.]. Personalized cancer vaccine design using AI-powered technologies //
Frontiers in Immunology. 2024.
37. Siew-Kee Low, Hitoshi Zembutsu, Yusuke Nakamura Breast cancer: The translation of big
genomic data to cancer precision medicine // Cancer Science. 2018. № 3 (109). C. 497–506.
38. Sohana Akter AI-Driven Precision Medicine: Transforming Personalized Cancer Treatment
2024. № 1 (2). C. 10–21.
39. Stefan Holdenrieder [и др.]. Pan-cancer screening by circulating tumor DNA (ctDNA) – recent
breakthroughs and chronic pitfalls // Journal of laboratory medicine. 2022. № 4 (46). C. 247–253.
40. Tuğra Alp Terzi Using Artificial Intelligence for Personalized Cancer Treatment 2024. № 1 (8).
C. 133–133.
41. William Huang, Chunli Zhao, Xiujun Fan Clinical Applications of Artificial Intelligence on
Accuracy of Cancer Prediction, Detection, and Diagnosis 2020. № 10 (5). C. 470–478.
42. Yao Yao, Frank Chen, Qingpeng Zhang Optimized patient-specific immune checkpoint
inhibitor therapies for cancer treatment based on tumor immune microenvironment modeling // Briefings
in Bioinformatics. 2024. № 6 (25).
43. Yuanli Wang, Dawu Zheng The importance of precision medicine in modern molecular
oncology. // Clinical Genetics. 2021. № 3 (100). C. 248–257.
44. Zodwa Dlamini The Application of AI in Precision Oncology: Tailoring Diagnosis, Treatment,
and the Monitoring of Disease Progression to the Patient 2023.C. 1–25.
45. Emerging Non‐invasive Molecular Biomarkers for Early Cancer Detection 2022. C. 229–250.
46. Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical
Considerations // American Society of Clinical Oncology educational book. 2022. № 42. C. 842–851.
47. DrOGA: an artificial intelligence solution for driver-status prediction of genomics mutations in
precision cancer medicine // IEEE Access. 2023. C. 1–1.
48. Effective Use of Computational Biology and Artificial Intelligence in the Domain of Medical
Oncology 2024.C. 228–252.
49. Cancer classification using deep learning techniques and multi-omics data integration //
International journal of research in advanced electronics engineering. 2024.
